Arsenic trioxide (As2O3) has been reported to severely reduce SETDB1 levels by inducing promyelocytic leukemia protein degradation (Cho et al., 2013) (R, R)-59 is a selective SETDB1-TTD small molecule inhibitor screened based on this concept that has been shown to inhibit SETDB1 in acute monocytic leukemia cells (Guo et al., 2021). This evidence concerns the gene SETDB1 and acute monocytic leukemia.